Literature DB >> 11370243

Prevention of exercise-induced cardiac hypertrophy in rats by chemical sympathectomy (guanethidine treatment).

I Ostman-Smith1.   

Abstract

The effect of 'chemical sympathectomy', produced by daily intraperitoneal injections of guanethidine sulphate for six weeks, was studied in sedentary rats and in rats chronically exercised by swimming. The guanethidine-treatment itself caused the following changes. There was a reduction in the rate of weight gain resulting in a 7% lower final body weight. Organ content of noradrenaline was decreased by 90% in spleen and submandibular glands and by 83% in the heart. Urinary excretion of noradrenaline was also decreased, but to a lesser degree, both during rest (45% lower) and after acute exercise (46% lower), while the urinary excretion of adrenaline was no different from that of controls. There was a compensatory adrenal hypertrophy in the guanethidine-treated rats, with a significant increase in adrenal catecholamine levels that was more pronounced for noradrenaline (+45%) than for adrenaline (+11%). Chronic physical exercise produced the expected degree of cardiac hypertrophy in untreated rats, but this adaptive cardiac hypertrophy was completely absent in the exercised guanethidine-treated rats. The results indicate, firstly that a good degree of chemical sympathectomy was obtained and that the persistence of a considerable urinary excretion of catecholamines in the guanethidine-treated rats was due to a compensatory increase in the secretory activity of the adrenal medulla. Secondly, it is suggested that the adaptive cardiac hypertrophy produced by chronic exercise is not caused by a direct effect of the increased work load on the cardiac muscle cell, but is instead mediated by release of a trophic factor from cardiac sympathetic nerves, probably noradrenaline itself but possibly a secretory protein.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 11370243     DOI: 10.1016/0306-4522(76)90102-0

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  11 in total

1.  Sympathetic control of cardiac myosin heavy chain gene expression.

Authors:  M P Gupta; M Gupta; E Dizon; R Zak
Journal:  Mol Cell Biochem       Date:  1996 Apr 12-26       Impact factor: 3.396

2.  Adaptational responses to prolonged beta-adrenoceptor blockade in adult rabbits.

Authors:  A E Raine; E M Vaughan Williams
Journal:  Br J Pharmacol       Date:  1980-10       Impact factor: 8.739

Review 3.  Effects of different antihypertensive drugs on left ventricular function.

Authors:  R Oliveri
Journal:  Drugs       Date:  1988       Impact factor: 9.546

4.  Changes in left ventricular mass during a double-blind study with chlorthalidone and slow-release nifedipine.

Authors:  L A Ferrara; G de Simone; M Mancini; M L Fasano; F Pasanisi; G Vallone
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

5.  Training-induced bradycardia and intrinsic heart rate in rats.

Authors:  E Nylander; K Sigvardsson; A Kilbom
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1982

6.  Hypertrophic smooth muscle. I. Size and shape of cells, occurrence of mitoses.

Authors:  G Gabella
Journal:  Cell Tissue Res       Date:  1979-09-02       Impact factor: 5.249

7.  Reduction by beta-adrenoceptor blockade of hypoxia-induced right heart hypertrophy in the rat.

Authors:  I Ostman-Smith
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

8.  Reduction by oral propranolol treatment of left ventricular hypertrophy secondary to pressure-overload in the rat.

Authors:  I Ostman-Smith
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

Review 9.  The 'athletic heart syndrome'. A critical review.

Authors:  K P George; L A Wolfe; G W Burggraf
Journal:  Sports Med       Date:  1991-05       Impact factor: 11.136

10.  Hypoxic cardiac hypertrophy is not inhibited by cardioselective or non-selective beta-adrenoceptor antagonists.

Authors:  P Dennis; E M Vaughan Williams
Journal:  J Physiol       Date:  1982-03       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.